Skip to main content

Table 4 Characteristics of local recurrent patients after curettage for GCTBa from 2008 to 2010

From: Clinical outcome of primary giant cell tumor of bone after curettage with or without perioperative denosumab in Japan: from a questionnaire for JCOG 1610 study

Sites

Campanacci grade

Pathological fracture at presentation

Time to recurrence (months)

Final joint preservation

Embolization before curettage

Tibia

II

No

25

Possible

No

Femur

II

No

60

Possible

Yes

Metatarsal bone

II

No

60

Impossible

Yes

Femur

III

No

6

Impossible

No

Tibia

III

No

36

Possible

Yes

Tibia

II

No

27

Possible

No

Fibula

II

No

6

Possible

No

Femur

III

No

11

Possible

No

Femur

II

No

28

Possible

No

Ulna

III

No

6

Possible

No

Femur

II

No

9

Possible

No

Tibia

II

No

21

Possible

No

Femur

II

No

24

Impossible

No

Femur

III

No

6

Possible

No

Radius

II

No

6

Impossible

No

Tibia

III

Yes

24

Possible

Yes

Tibia

III

Yes

14

Possible

No

Fibula

II

No

35

Possible

No

Femur

III

Yes

21

Possible

No

Lumbar spine

III

No

60

Not available

No

Femur

II

No

12

Possible

No

Femur

III

Yes

5

Possible

No

Femur

II

No

6

Possible

No

Talus

II

No

12

Possible

No

Femur

III

Yes

30

Possible

No

Femur

III

No

6

Possible

No

Femur

III

No

22

Possible

No

Femur

III

No

7

Possible

No

Femur

II

No

17

Possible

No

Femur

I

No

7

Possible

No

  1. aGCTB, giant cell tumor of bone